title: Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma.
abstract: With the success of targeted monoclonal antibody therapy in non-Hodgkin's lymphoma, attempts were made to further improve efficacy through the addition of a radioisotope. A goal of radioimmunotherapy is to utilize the monoclonal antibody to deliver radiation to a tumor bed with relatively limited toxicity to the surrounding normal tissues. I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin's lymphoma (NHL). For more than a decade now, radiolabeled tositumomab has principally been evaluated in low-grade and transformed low-grade NHL patients with proven efficacy in both the up-front and salvage settings. Studies have included its use as a single agent, in combination with chemotherapy and as part of a conditioning regimen for autologous stem cell transplantation. These data suggest that this agent has an important role in the treatment of patients with B cell lymphoma.
authors.affiliation: Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA.
authors.forename: Biree
authors.initials: B
authors.lastname: Andemariam
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: Blood. 2002 May 1;99(9):3158-62
references.pmid: 11964278
references.citation: Blood. 2003 Oct 1;102(7):2351-7
references.pmid: 12750161
references.citation: J Clin Oncol. 1993 Apr;11(4):644-51
references.pmid: 8478660
references.citation: N Engl J Med. 1993 Aug 12;329(7):459-65
references.pmid: 7687326
references.citation: J Clin Oncol. 2000 Mar;18(6):1316-23
references.pmid: 10715303
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1469-79
references.pmid: 15084620
references.citation: Blood. 2000 Aug 15;96(4):1259-66
references.pmid: 10942366
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4143-9
references.pmid: 16896003
references.citation: J Clin Oncol. 2005 Jan 20;23(3):461-7
references.pmid: 15534357
references.citation: J Clin Oncol. 1996 Jul;14(7):1974-81
references.pmid: 8683227
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7565-73
references.pmid: 16186600
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5696-704
references.pmid: 16110029
references.citation: N Engl J Med. 2005 Feb 3;352(5):441-9
references.pmid: 15689582
references.citation: J Clin Oncol. 1995 Jan;13(1):140-7
references.pmid: 7799014
references.citation: J Clin Oncol. 2005 Feb 1;23(4):712-9
references.pmid: 15613695
references.citation: Blood. 2000 Nov 1;96(9):2934-42
references.pmid: 11049969
references.citation: Blood. 2005 Jun 15;105(12):4576-82
references.pmid: 15731177
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7985-93
references.pmid: 16204016
references.citation: J Clin Oncol. 2003 Mar 1;21(5):897-906
references.pmid: 12610191